Siemens Healthcare has added new functions to Syngo Embolization Guidance to simplify and accelerate the minimally invasive embolization of benign tumors such as myomas. The new version of the imaging software assists with treatment planning and delivery and makes it possible to check treatment outcomes. Syngo Embolization Guidance can speed up interventions as compared with previous embolization procedures, meaning that both contrast medium and dose can be reduced. This makes the occlusion of the blood vessels supplying the myoma easier on the patient than conventional methods.
The new version of Syngo Embolization Guidance from Siemens enables physicians to mark both the myoma and the blood vessels supplying the tumor on the pre-intervention CT (computed tomography) or MRT (magnetic resonance tomography) images. The software calculates the tumor volume and the access path to the myoma for the catheter automatically and shows both in the 3D planning image. Superimposing this image on the live fluoroscopic image during the intervention enables the radiologist to position the catheter easier than has previously been the case and largely removes the need for contrast medium, as the path is already marked and segmented in the 3D image. Treating myomas with Syngo Embolization Guidance is thus easier on the patient. Myomas (uterine leiomyomas) are benign thickenings of the myometrium. The Robert Koch Institute explains in its reporting to the German Federal Health Monitoring System in 2007 that myomas occur in significant numbers in around one third of women from the age of 35 onward in our part of the world1.
The traditional technique for myoma treatment involves the surgical removal of the tumors in an operation. A new minimally invasive method involving the occlusion of blood vessels has become established over recent years. Known as embolization, this technique sees a catheter inserted into the patient's vascular system through a very small access point, usually in the groin, and guided to the tumor. The catheter is navigated through the blood stream using a fluoroscopy system. The position of the catheter in the patient's body is displayed on screen in 2D images from an angiography unit, with contrast medium helping to make the area of interest stand out from the surrounding tissue. Key to this technique is the ability to bring the catheter into a position from which the blood vessels supplying the tumor can be occluded. Once the catheter is in place, emboli, for example very small particles of plastic, are injected directly into the blood vessels that supply the myoma until the blood supply to the benign tumor has been stopped. Deprived of essential nutrients and oxygen, the myomas shrink and eventually die.
The product mentioned herein is not commercially available. Due to regulatory reasons its future availability cannot be guaranteed.
The Siemens Healthcare Sector is one of the world’s largest healthcare solution providers and a leading manufacturer and service provider in the fields of medical imaging, laboratory diagnostics, hospital information technology and hearing instruments. It offers solutions covering the entire supply chain under one roof - from prevention and early detection to diagnosis and on to treatment and aftercare. By optimizing clinical workflows oriented toward the most important clinical pictures, Siemens also strives to make healthcare faster, better and, at the same time, less expensive. Siemens Healthcare currently has some 48,000 employees worldwide and is present throughout the world. During fiscal 2010 (up to September 30) the Sector posted sales worth 12.4 billion euros and profits of around 750 million euros.
1 Robert Koch Institute, Ed.: Vol. 37 Gebärmuttererkrankungen [Hysteropathy], from the series "Gesundheitsberichterstattung des Bundes" [German Federal Health Monitoring], Berlin, January 2007
Marion Bludszuweit | Siemens Healthcare
3-D visualization of the pancreas -- new tool in diabetes research
15.03.2017 | Umea University
New PET radiotracer identifies inflammation in life-threatening atherosclerosis
02.03.2017 | Society of Nuclear Medicine
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
23.03.2017 | Life Sciences
23.03.2017 | Power and Electrical Engineering
23.03.2017 | Earth Sciences